Original Research
Accepted on 02 Feb 2026
Inferring Tumor Immune Microenvironment (TIME)-Related Risk States from Pretreatment H&E Pathomics and Clinical Biomarkers to Predict Checkpoint Inhibitor Pneumonitis in Advanced NSCLC: A Multicenter Multimodal Study
in Cancer Immunity and Immunotherapy